Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis

This study has been completed.
Information provided by:
Laboratoires NEGMA
ClinicalTrials.gov Identifier:
First received: February 26, 2007
Last updated: March 3, 2010
Last verified: October 2007
Some inflammation mediators, notably IL-1, are implied in the joint degeneration phenomena of osteoarthritis. The aim of this study is to confirm in vivo the favourable effect of diacerhein on IL-1 and also to appreciate its effect on other synovial inflammation mediators.

Condition Intervention Phase
Drug: Diacerhein
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Exploratory Study of Some Synovial Fluid Inflammation Mediatorsunder Diacerhein in Knee Osteoarthritis Patients. Phase IV Study.

Resource links provided by NLM:

Further study details as provided by Laboratoires NEGMA:

Primary Outcome Measures:
  • Synovial concentration of IL-1

Secondary Outcome Measures:
  • Synovial concentration of IL-6

Estimated Enrollment: 96
Study Start Date: March 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   45 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Painful osteoarthritis
  • Hydarthrosis (synovial effusion)

Exclusion Criteria:

  • large effusion
  • severe pathologies
  • anti-osteoarthritic treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00440661

Canada, Quebec
Rheumatologic Institut of Montreal
Montreal, Quebec, Canada, H2L1S6
Sponsors and Collaborators
Laboratoires NEGMA
Principal Investigator: Jean-Pierre RAYNAULD, MD Institut de Rhumatologie de Montreal
  More Information

Responsible Party: Patrick Darses, Negma-Lerads
ClinicalTrials.gov Identifier: NCT00440661     History of Changes
Other Study ID Numbers: HEC/ART06572N  109196 
Study First Received: February 26, 2007
Last Updated: March 3, 2010
Health Authority: Canada: Health Canada

Keywords provided by Laboratoires NEGMA:
Osteoarthritis, IL-1

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on May 22, 2016